Long-term benefit after allergen immunotherapy to HDM in elderly patients with allergic rhinitis.
| Autor: | Bożek A; Clinical Department of Internal Medicine, Dermatology and Allergology in Zabrze, Medical University of Silesia in Katowice, Poland., Bogacz-Piaseczyńska A; Clinical Department of Internal Medicine, Dermatology and Allergology in Zabrze, Medical University of Silesia in Katowice, Poland., Miodońska M; Clinical Department of Internal Medicine, Dermatology and Allergology in Zabrze, Medical University of Silesia in Katowice, Poland., Sadowska D; Clinical Department of Internal Medicine, Dermatology and Allergology in Zabrze, Medical University of Silesia in Katowice, Poland. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Postepy dermatologii i alergologii [Postepy Dermatol Alergol] 2023 Oct; Vol. 40 (5), pp. 688-692. Date of Electronic Publication: 2023 Jul 19. |
| DOI: | 10.5114/ada.2023.129942 |
| Abstrakt: | Introduction: Allergen immunotherapy (AIT) is an effective therapy for allergic rhinitis and may have long-term benefits. However, these benefits have not been strictly defined for older people. Aim: The evaluation of the effectiveness of AIT in patients over 60 with allergic rhinitis and house dust mites (HDM) allergy over a period of 7 years was performed. Material and Methods: Patients after three years of HDM-AIT were observed to assess the sustained clinical effect of treatment. The average adjusted symptom score (AAdSS) and sIgG4 were monitored for 7 years after sublingual (SLIT) and injection AIT (SCIT). Results: After 3 years of HDM-AIT, a significant clinical effect was observed in the group after SLIT and SCIT based on AAdSS compared to the baseline and the placebo group ( p < 0.05). After 7 years of follow-up, there was a sustained trend of decrease in clinical symptoms in desensitized patients relative to placebo. Serum sIgG4 was constantly present in all desensitized patients. Conclusions: AIT may be beneficial for treating seniors with allergic rhinitis and allergies to house dust mites. Competing Interests: The authors declare no conflict of interest. (Copyright: © 2023 Termedia Sp. z o. o.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|